FDA Approved: SANDOSTATIN LAR DEPOT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

FDA approved a supplemental application for Sandostatin LAR Depot (octreotide acetate) from Novartis, resulting in an updated labeling to reflect the approved s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly
• Carcinoid Tumor
• Vipoma

Drugs mentioned

• SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)

Snippet

SUPPL AP for SANDOSTATIN LAR DEPOT (OCTREOTIDE ACETATE)